BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25593917)

  • 1. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.
    van de Watering FC; Rijpkema M; Robillard M; Oyen WJ; Boerman OC
    Front Med (Lausanne); 2014; 1():44. PubMed ID: 25593917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pretargeting system for tumor PET imaging and radioimmunotherapy.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Frampas E; Faivre-Chauvet A; Rauscher A; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
    Front Pharmacol; 2015; 6():54. PubMed ID: 25873896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted molecular imaging and radioimmunotherapy.
    Goldenberg DM; Chang CH; Rossi EA; J W; McBride ; Sharkey RM
    Theranostics; 2012; 2(5):523-40. PubMed ID: 22737190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
    Lindegren S; Frost SH
    Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
    Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
    Chang CH; Sharkey RM; Rossi EA; Karacay H; McBride W; Hansen HJ; Chatal JF; Barbet J; Goldenberg DM
    Mol Cancer Ther; 2002 May; 1(7):553-63. PubMed ID: 12479274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeting: A Path Forward for Radioimmunotherapy.
    Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
    J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
    Bodet-Milin C; Bailly C; Touchefeu Y; Frampas E; Bourgeois M; Rauscher A; Lacoeuille F; Drui D; Arlicot N; Goldenberg DM; Faivre-Chauvet A; Barbet J; Rousseau C; Kraeber-Bodéré F
    Front Med (Lausanne); 2019; 6():124. PubMed ID: 31214593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.
    Goldenberg DM; Chatal JF; Barbet J; Boerman O; Sharkey RM
    Update Cancer Ther; 2007 Mar; 2(1):19-31. PubMed ID: 18311322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in pretargeted radioimmunotherapy.
    Gruaz-Guyon A; Raguin O; Barbet J
    Curr Med Chem; 2005; 12(3):319-38. PubMed ID: 15723622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
    J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
    Zhu H; Jain RK; Baxter LT
    J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabody Pretargeting with Click Chemistry In Vivo.
    van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
    J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.